禾賽-W(02525.HK)香港IPO發行價定為每股212.8港元 淨籌40.05億港元
格隆匯9月15日丨禾賽-W(02525.HK)公吿,公司全球發售1955萬股股份,每股發售股份212.80港元,所得款項淨額40.05億港元。香港公開發售股份數目佔全球發售股份數目10%,獲認購168.65倍;國際發售股份數目佔全球發售股份90%,獲認購14.09倍。假設全球發售於香港時間2025年9月16日(星期二)上午八時正或前成為無條件,B類普通股預計將於香港時間2025年9月16日(星期二)上午九時正開始在聯交所買賣。B類普通股將以每手20股B類普通股為買賣單位,B類普通股的股份代號將為2525。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.